LEADER 02927oam 2200445zu 450 001 9911019210103321 005 20210807003037.0 010 $a3-527-62086-9 035 $a(CKB)1000000000687481 035 $a(SSID)ssj0000388113 035 $a(PQKBManifestationID)12154469 035 $a(PQKBTitleCode)TC0000388113 035 $a(PQKBWorkID)10430969 035 $a(PQKB)11605829 035 $a(NjHacI)991000000000687481 035 $a(EXLCZ)991000000000687481 100 $a20160829d1999 uy 101 0 $aeng 135 $aur||||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aBiotechnology, Recombinant Proteins, Monoclonal Antibodies, and Therapeutic Genes. Vol. 5 210 31$a[Place of publication not identified]$cWiley VCH Imprint$d1999 215 $a1 online resource (xvi, 562 pages) $cillustrations 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a3-527-28315-3 327 $aTypes and Function of Proteins -- Sequence and Structure of Proteins -- Protein Interactions -- In vitro Folding of Inclusion Body Proteins on an Industrial Scale -- Medical Applications of Recombinant Proteins in Humans and Animals -- Enzymes for Industrial Applications -- Antibody Engineering and Expression -- Manufacture of Therapeutic Antibodies -- Use of Antibodies for Immunopurification -- Preclinical Testing of Antibodies: Pharmacology, Kinetics and Immunogenicity -- Preclinical Testing of Antibodies : Safety Aspects -- Therapeutic Applications of Monoclonal Antibodies : A Clinical Overview -- Antibodies for Sepsis: Some Lessons Learnt -- An Engineered Human Antibody for Chronic Therapy : CDP571 -- Antibody Targeted Chemotherapy -- ReoPro Clinical Development : A Case Study -- Overview of Gene Therapy -- Viral Vectors for Gene Therapy -- Non-Viral Vectors for Gene Therapy -- Issues of Large-Scale Plasmid DNA Manufacturing -- Gene Therapy for HIV Infection -- Regulation of Antibodies and Recombinant Proteins -- Regulation of Human Gene Therapy -- Economic Considerations. 330 $aIn the field of medicinal biotechnology three major developments have caused a revolution in research that has a lot of innovative effects on clinical medicine and future applications on humans. With the availability of tailored recombinant proteins and the opportunity to produce high amounts of monoclonal antibodies new diagnostic applications have emerged and many therapeutic perspectives, e.g. in the treatment of multiple sclerosis and of cancer, are being discussed today. 606 $aBiotechnology 615 0$aBiotechnology. 676 $a660.6 700 $aMountain$b A$01838779 702 $aSchomburg$b Dietmar 702 $aNey$b U. M 801 0$bPQKB 906 $aBOOK 912 $a9911019210103321 996 $aBiotechnology, Recombinant Proteins, Monoclonal Antibodies, and Therapeutic Genes. Vol. 5$94417848 997 $aUNINA LEADER 01633nam0 2200373 i 450 001 RMG0287619 005 20251003044339.0 010 $a8814174067 010 $a9788814174063 020 $aIT$b2012-3526 100 $a20200601d2012 ||||0itac50 ba 101 | $aita 102 $ait 181 1$6z01$ai $bxxxe 182 1$6z01$an 183 1$6z01$anc$2RDAcarrier 200 1 $aDiritti fondamentali e giustizia costituzionale$eesperienze europee e Nord-americana$fa cura di Silvio Gambino 210 $aMilano$cGiuffrè$d2012 215 $aXI, 446 p.$d24 cm 225 | $aUniversità degli studi della Calabria, Dipartimento di scienze giuridiche, Area giuspubblicistica$v31 410 0$1001CFI0618737$12001 $aUniversità degli studi della Calabria, Dipartimento di scienze giuridiche, Area giuspubblicistica$v31$171201$aUniversità degli studi della Calabria$b : Dipartimento di scienze giuridiche$3CFIV219931 606 $aDiritto costituzionale comparato$2FIR$3CFIC002611$9E 606 $aGiustizia costituzionale$2FIR$3MILC025887$9E 676 $a323.0943$9$v21 676 $a342.4085$9Diritti e attività personali. Europa$v22 702 1$aGambino$b, Silvio$f <1946- >$3CFIV000573 801 3$aIT$bIT-000000$c20200601 850 $aIT-BN0095 901 $bNAP 01$cD $n$ 912 $aRMG0287619 950 0$aBiblioteca Centralizzata di Ateneo$d 01D (S) 3 788$e 01S 0090037885 VMA 1 v.$fY $h20150911$i20150911 977 $a 01 996 $aDiritti fondamentali e giustizia costituzionale$967267 997 $aUNISANNIO